Please use this identifier to cite or link to this item:
http://bura.brunel.ac.uk/handle/2438/27163
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cilliers, K | - |
dc.contributor.author | Menezes, A | - |
dc.contributor.author | Webber, T | - |
dc.contributor.author | Dockrell, HM | - |
dc.contributor.author | Cliff, JM | - |
dc.contributor.author | Kleynhans, L | - |
dc.contributor.author | Chegou, NN | - |
dc.contributor.author | du Plessis, N | - |
dc.contributor.author | Loxton, AG | - |
dc.contributor.author | Kidd, M | - |
dc.contributor.author | Djoba Siawaya, JF | - |
dc.contributor.author | Ronacher, K | - |
dc.contributor.author | Walzl, G | - |
dc.date.accessioned | 2023-09-12T10:09:43Z | - |
dc.date.available | 2023-09-12T10:09:43Z | - |
dc.date.issued | 2021-04-10 | - |
dc.identifier | ORCID iDs: Karen Cilliers https://orcid.org/0000-0001-7309-3277; Tariq Webber https://orcid.org/0000-0002-1772-4502; Jacqueline M. Cliff https://orcid.org/0000-0002-5653-1818; Nelita du Plessis https://orcid.org/0000-0001-7881-925X; Martin Kidd https://orcid.org/0000-0002-4887-7296. | - |
dc.identifier | 102082 | - |
dc.identifier.citation | Cilliers, K. et al. (2021) 'Mycobacterium tuberculosis-stimulated whole blood culture to detect host biosignatures for tuberculosis treatment response', Tuberculosis, 128, 102082, pp. 1 - 9. doi: 10.1016/j.tube.2021.102082. | en_US |
dc.identifier.issn | 1472-9792 | - |
dc.identifier.uri | https://bura.brunel.ac.uk/handle/2438/27163 | - |
dc.description | Supplementary data are available online at https://www.sciencedirect.com/science/article/pii/S1472979221000329?via%3Dihub#appsec1 . | en_US |
dc.description.abstract | Host markers to monitor the response to tuberculosis (TB) therapy hold some promise. We evaluated the changes in concentration of Mycobacterium tuberculosis (M.tb)-induced soluble biomarkers during early treatment for predicting short- and long-term treatment outcomes. Whole blood samples from 30 cured and 12 relapsed TB patients from diagnosis, week 1, 2, and 4 of treatment were cultured in the presence of live M.tb for seven days and patients followed up for 24 weeks after the end of treatment. 57 markers were measured in unstimulated and antigen-stimulated culture supernatants using Luminex assays. Top performing multi-variable models at diagnosis using unstimulated values predicted outcome at 24 months after treatment completion with a sensitivity of 75.0% (95% CI, 42.8–94.5%) and specificity of 72.4% (95% CI, 52.8–87.3%) in leave-one-out cross validation. Month two treatment responder classification was correctly predicted with a sensitivity of 79.2% (95% CI, 57.8–92.9%) and specificity of 92.3% (95% CI, 64.0–99.8%). This study provides evidence of the early M.tb-specific treatment response in TB patients but shows that the observed unstimulated marker models are not outperformed by stimulated marker models. Performance of unstimulated predictive host marker signatures is promising and requires validation in larger studies. | en_US |
dc.description.sponsorship | Bill and Melinda Gates Foundation (TB Drug Accelerator Program, grant number 48941); Action TB by GSK; EDCTP (01.T.d1, Grant number 2004.1.R.d1); the South African Technology for Human Resources and Industry Program (THRIP); and an International Collaborations in Infectious Diseases Research grant from the National Institute of Allergy and Infectious Diseases (grant number 5U01IA115619). This research was also partially funded by the South African government through the South African Medical Research Council, through a grant from the Strategic Health Innovations Partnership (SHIP) unit, by the South African National Research Foundation through a South African Research Chair Initiative: Biomarkers for TB (grant number 86535) and a South African Department of Science and Innovation/National Research Foundation funded Centre of Excellence in Biomedical Tuberculosis Research. | en_US |
dc.format.extent | 1 - 9 | - |
dc.format.medium | Print-Electrlonic | - |
dc.language | English | - |
dc.language.iso | en_US | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | Copyright © 2021 Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Published in final edited form as: Tuberculosis (Edinb). 2021 May ; 128: 102082 https://doi.org/10.1016/j.tube.2021.102082. | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | - |
dc.subject | antigen-specific | en_US |
dc.subject | biomarkers | en_US |
dc.subject | relapse | en_US |
dc.subject | slow responders | en_US |
dc.subject | treatment response | en_US |
dc.subject | tuberculosis | en_US |
dc.title | Mycobacterium tuberculosis-stimulated whole blood culture to detect host biosignatures for tuberculosis treatment response | en_US |
dc.type | Article | en_US |
dc.identifier.doi | https://doi.org/10.1016/j.tube.2021.102082 | - |
dc.relation.isPartOf | Tuberculosis | - |
pubs.publication-status | Published | - |
pubs.volume | 128 | - |
dc.identifier.eissn | 1873-281X | - |
dc.rights.holder | Elsevier | - |
Appears in Collections: | Dept of Life Sciences Research Papers |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
FullText.pdf | Copyright © 2021 Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. Published in final edited form as: Tuberculosis (Edinb). 2021 May ; 128: 102082 https://doi.org/10.1016/j.tube.2021.102082. | 2.1 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License